Ep93: Jay Bradner & Andy Plump on Mentoring Young Scientists

Episode Summary

Executive Summary: Jay Bradner and Andy Plump argued that biopharma and academia are converging in rigor, teamwork, and translational focus, while industry offers stronger mentoring, more resources, and clearer career on-ramps. They emphasized structured postdoc and internship programs, metrics-driven diversity efforts, and the need to actively cultivate talent from underrepresented groups rather than rely on sink-or-swim models.

Main Topics: Academia vs. industry: shrinking the disconnect (Priority: 5/5): Both leaders said the old cultural divide between academia and industry is narrowing. Industry has become more scholarly under reproducibility pressures, while academia has become more translational and startup-oriented. Mentorship as a core organizational responsibility (Priority: 5/5): They argued that mentorship should be structured, intentional, and embedded in company culture, not left to chance. Programs like assigned mentors and leadership training were presented as essential for young scientists. Postdoc and internship pipelines into biopharma (Priority: 5/5): Novartis and Takeda described formal training pathways for trainees and early-career scientists, including innovation postdocs, internships, and rotational programs designed to teach drug discovery and broader industry skills. Diversity, equity, and inclusion as measurable business priorities (Priority: 5/5): The discussion centered on pay equity, representation, hiring slates, attrition, and leadership diversity. Both speakers said companies must track concrete metrics and intervene when leadership teams lack diversity. Career path flexibility and advice for young scientists (Priority: 4/5): They advised young scientists to focus first on deep expertise, then broaden into cross-functional skills if useful. Career moves between academia, biotech, and pharma were framed as increasingly bi-directional and individualized. Pandemic-era work, engagement, and hybrid culture (Priority: 4/5): Andy and Jay reflected on remote work, employee well-being, and the need to support productivity and inclusion during COVID-19. They noted virtual work changed participation dynamics and required new management practices. Talent development, leadership, and the future of biopharma (Priority: 4/5): The speakers linked leadership diversity and structured development to stronger innovation, better decision-making, and a healthier talent pipeline for the future of R&D.

Key Arguments: Industry is not a lesser or easier destination; it can be as intellectually rigorous as academia and is often more directly patient-focused. Formal training programs in industry can serve as true on-ramps for drug discovery careers, especially for scientists trained broadly rather than specifically in therapeutics. Mentorship should be systematic: assigned mentors, leadership training, and a culture of openness make a bigger difference than informal advice alone. Diversity must be measured through metrics such as pay equity, attrition, hiring slates, and leadership composition; progress does not happen without accountability. Young scientists should build a strong specialist foundation first, then broaden into generalist or cross-functional skills once they have depth. Career transitions between academia, biotech, and pharma are increasingly reversible and common; the best fit depends more on science, culture, and people than company size. The pandemic exposed workload and caregiving inequities, especially for women, but also showed that well-managed virtual work can keep teams engaged. Leadership teams should be diverse enough to avoid groupthink; in some cases, investors and executives should explicitly challenge homogeneous founding or management teams.

Data Points: Innovation postdoc applications: 1,500 applicants for 14 spots - Jay described strong demand for Novartis’s drug-hunting training program. Innovation postdoc duration: 2 to 4 years - Jay said the program is designed as a meaningful but bounded training period. Novartis postdocs: Over 100 postdocs - Jay noted that NIBR has an established broader postdoc class beyond the innovation postdoc. Takeda Boston R&D workforce: About 3,500 R&D scientists and other employees - Andy cited the size of Takeda’s Boston-based R&D presence. Takeda Boston share of R&D: About 70% - Andy said the majority of Takeda’s organization is in Boston. Novartis global presence: More than 40 countries - Andy described Takeda’s global operations and Novartis similarly described broad international reach. Women in biotech leadership: 30% - Jay cited industry-wide leadership representation data. Women on biotech boards: 18% - Jay cited board-level underrepresentation in biotech. Biotech companies without a woman on the board: 48.5% - Jay referenced a Deerfield study on venture-backed healthcare companies. Women in academic tenure: 24% - Jay used this to illustrate attrition up the academic ladder. Women in Novartis management: 45% women, 55% men - Jay said Novartis is close to parity in management. Nationalities at Novartis: Over 149 - Jay cited Novartis’s global diversity. Board representation at Novartis: About one quarter female - Jay described progress but said more remains to be done. Takeda new hires during pandemic: About 600 - Andy said the company hired many Boston-area R&D employees virtually in 2020. Average tenure at NIBR: 10 years - Jay noted strong retention in the organization. Typical role tenure at NIBR: Less than 3 years - Jay used this to show movement and career development within the company. Takeda R&D scientists and employees in Boston: About 3,500 - Andy gave the scale of the Boston R&D hub. NIH budget growth described by questioner: Doubling of the NIH budget - A listener asked about the workforce effects of the earlier NIH budget surge. International sites at Novartis: Research sites in 6 global sites - Andy emphasized global connectivity and recruitment.

Pivotal Quotes: "I love the patient focus. You know, people make fun at us because of the fact that we have underlying profits. But to be very fair, profits and patient focus are not mutually exclusive." — Andy Plump: On why industry can be mission-driven rather than purely commercial. "We start a project in my old lab expecting it might be 13 authors and four institutions. We start a project in NIBR expecting it might be, you know, 40 scientists from, you know, eight of our research units." — Jay Bradner: On the similarity between elite academic and industry science being team-based and interdisciplinary. "You need to start a deep and grounded specialist and become a multilingual generalist." — Jay Bradner: On how early-career scientists should think about specialization versus breadth.

Implications: Biopharma leaders are increasingly expected to build talent pipelines, mentor deliberately, and measure inclusion. For listeners, the message is that industry careers are more accessible, flexible, and scientifically rigorous than older stereotypes suggest.